BioLine Rx (XTAE:BLRX) Other Long Term Assets : ₪-0.00 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Other Long Term Assets?

BioLine Rx's other long-term assets for the quarter that ended in Dec. 2023 was ₪-0.00 Mil.

BioLine Rx's quarterly other long-term assets increased from Jun. 2023 (₪0.00 Mil) to Sep. 2023 (₪0.00 Mil) but then stayed the same from Sep. 2023 (₪0.00 Mil) to Dec. 2023 (₪-0.00 Mil).

BioLine Rx's annual other long-term assets increased from Dec. 2021 (₪-0.00 Mil) to Dec. 2022 (₪-0.00 Mil) but then declined from Dec. 2022 (₪-0.00 Mil) to Dec. 2023 (₪-0.00 Mil).

BioLine Rx Other Long Term Assets Historical Data

The historical data trend for BioLine Rx's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Other Long Term Assets Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															-	-	-	-	-

BioLine Rx Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.